Send to

Choose Destination
Am J Ther. 2013 Nov-Dec;20(6):618-21. doi: 10.1097/MJT.0b013e31826232dc.

Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.

Author information

1Department of Translational Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Departments of 2Biostatics 3Therapeutic Area Metabolism, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.


Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor with a primarily nonrenal route of excretion. Consequently, renal impairment should not substantially affect drug exposure. This analysis was undertaken to compare steady-state trough concentrations of linagliptin among patients with type-2 diabetes receiving linagliptin 5 mg in phase 3 studies. Data were pooled from 3 randomized studies from the global phase 3 program of linagliptin (5 mg daily in each) in patients with type-2 diabetes. These studies were selected for their inclusion of pharmacokinetic data. Linagliptin plasma concentrations were available for 969 patients who were determined by estimated glomerular filtration rate to have normal renal function (n = 438), mild renal impairment (RI) (n = 429), moderate RI (n = 44), or severe RI (n = 58). In patients with normal renal function, the geometric mean linagliptin trough concentration (coefficient of variation) was 5.93 nmol/L (56.3%); in patients with mild, moderate, or severe RI, geometric mean concentrations were 6.07 nmol/L (62.9%), 7.34 nmol/L (58.6%), and 8.13 nmol/L (49.8%), respectively. In patients with type-2 diabetes, RI had a minor effect on linagliptin exposure. Therefore, neither dose-adjustment nor drug-related monitoring of estimated glomerular filtration rate is necessary for patients with RI.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center